logo
Plus   Neg
Share
Email

AstraZeneca Announces Approval For Tagrisso In China - Quick Facts

AstraZeneca (AZN.L,AZN) said Tagrisso has received marketing authorisation in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer. The company said the approval from China's National Medical Products Administration followed the Priority Review Pathway and is based on results from the Phase III FLAURA trial.

Tagrisso was approved in China in 2017 and added to the National Reimbursement Drug List effective from January 2019 for the 2nd-line treatment of adult patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT